by | Jun 21, 2022 | Uncategorized
In this video, Paul Richardson, MD, director of clinical research at Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discusses the phase III DETERMINATION study in multiple myeloma presented at ASCO Annual Meeting.Richardson discusses one of the...
by | Jun 21, 2022 | Uncategorized
In this video, Paul Richardson, MD, director of clinical research at Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discusses the phase III DETERMINATION study in multiple myeloma presented at ASCO Annual Meeting.Richardson introduces the...
by | Jun 21, 2022 | Uncategorized
CHICAGO — A single dose of an investigational chimeric antigen receptor T-cell therapy induced an objective response in nearly 90% of patients with relapsed or refractory multiple myeloma, phase 1 study results showed.Data from the trial — presented at ASCO Annual...
by | Jun 17, 2022 | Uncategorized
CHICAGO — Teclistamab continued to demonstrate durable efficacy for patients with relapsed or refractory multiple myeloma, according to results from the phase 1/phase 2 MajesTEC-1 trial.Updated results from the trial — presented at ASCO Annual Meeting and published...
by | Jun 16, 2022 | Uncategorized
Source: Cure Today articles The best advocate for a patient with cancer is someone who knows exactly what they’re going through, noted a multiple myeloma survivor. Read More
by | Jun 13, 2022 | Uncategorized
Source: Cure Today articles Experts discuss kidney cancer, multiple myeloma and MPN updates. Read More
